United Therapeutics Corp of Maryland, USA, has entered into a strategicalliance with Grupo Ferrer Internacional, based in Barcelona, Spain, for the distribution of Uniprost, the former's investigational prostacyclin drug for the treatment of pulmonary hypertension. The territories covered by the deal are Spain, France, Germany, Italy, Portugal, Greece and Belgium, as well as Mexico and all countries in Latin America.
United recently completed its pivotal trial for Uniprost, and the company is hoping to get approval for the treatment from the US Food and Drug Administration by the first quarter of 2001 (Marketletter May 8). In a press statement, Ferrer was described by the US firm as "a leading pharmaceutical company in Europe with extensive operations in the Americas and expertise in chronic-care therapies," and it was claimed that the Spanish group constitutes "the ideal partner for launching Uniprost within multiple countries in two hemispheres.''
A spokesman for Ferrer said that the company has gained significant experience to establish the logistics for distribution of life-saving drugs to customers and that "Uniprost fits perfectly into our specialty pharmaceutical portfolio."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze